FDA Approves Tymlos as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture
Radius Health, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Tymlos (abaloparatide), a parathyroid hormone related peptide [PTHrP(1-34)] analog, as a treatment to increase bone density in men with osteoporosis at high risk of fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or in patients who have failed or are intolerant to other available osteoporosis therapy.
Tymlos is a man-made form of parathyroid hormone that exists naturally in the body.
